Technologies
PDF


WARF: P120204US02

A Novel Series of Antimicrobials Target Bacteria Membranes to Overcome Antibiotic Resistance


INVENTORS -

Douglas Weibel, Ye Jin Eun, Marie Foss, Katherine Hurley

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a class of antimicrobial compounds that specifically target the membranes both of Gram-positive and Gram-negative bacteria.
OVERVIEWDrug-resistant pathogens continue to emerge as the rate of the development of new antimicrobials to combat them continues to decline. Alarmingly, slow-growing bacteria associated with dangerous and prolonged infections are able to survive many classes of clinical antibiotics. For example, β-lactam antibiotics kill rapidly growing cells, but are ineffectual against dormant bacteria. Treating infections with ineffective antibiotics can lead to long-term problems including bacterial drug resistance and relapse.

An effective strategy for combatting slow-growing bacteria is to target their lipid membranes. One-third of all proteins in bacteria are associated with membranes and disrupting this structure inhibits vital cell processes including respiration and energy transduction. The effectiveness of membrane-active drugs is well known. However, most have proven unsuccessful against Gram-negative bacteria, including bacteria of the genera Escherichia, Salmonella, Shigella, Pseudomonas, Helicobacter and Legionella.
THE INVENTIONUW–Madison researchers have developed a novel series of antimicrobial compounds that target the membranes of Gram-positive and Gram-negative bacteria, and are effective both against actively growing and stationary bacteria.

The series of compounds are analogs and derivatives of DCAP, or (2-((3-(3,6-dichloro-9H-carbazol-9-yl)-2-hydroxypropyl)amino)-2-(hydroxymethyl)propane-1,3-diol).

This series of compounds disrupts the bacterial cell envelope and causes cell death, and has only minor effects on eukaryotic cells. With this discovery, new antimicrobials based on DCAP analogs and derivatives could be used to combat resistant bacterial cells.
APPLICATIONS
  • Treating and preventing bacterial infections
  • Inhibiting biofilms
  • Cleaning bacterial contamination
KEY BENEFITS
  • Potential scaffold for new broad-spectrum antibiotics
  • Combats both Gram-negative and Gram-positive bacteria
  • Works against stationary and actively growing cells
  • Minimal harm to host cells
ADDITIONAL INFORMATION
For More Information About the Inventors
Publications
  • Eun Y.-J., Foss M.H., Kiekebusch D., Pauw D.A., Thanbichler M., Westler, W.M. and Weibel, D.B. 2012. DCAP: A Broad-Spectrum Antibiotic That Targets the Cytoplasmic Membrane of Bacteria. J. Am. Chem. Soc. 134, 11322-11325.
Contact Information
For current licensing status, please contact John Nagel at jnagel@warf.org or 608-960-9848.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.